tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neuronetics Reports Q2 2025 Financial Results Surge

Story Highlights
  • Neuronetics reported a 132% revenue increase in Q2 2025, driven by the Greenbrook acquisition.
  • The company reduced operational cash use to $3.5 million and secured $10 million in additional funding.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Neuronetics Reports Q2 2025 Financial Results Surge

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Neuronetics ( (STIM) ) is now available.

Neuronetics, Inc. announced its financial and operational results for the second quarter of 2025, highlighting a significant revenue increase of 132% compared to the same period in 2024, primarily due to the acquisition of Greenbrook TMS Inc. The company reported a total revenue of $38.1 million, with U.S. clinic revenue reaching $23.0 million. Despite a decrease in gross margin to 46.6% from 74.0% in the previous year, the company reduced cash used in operations to $3.5 million, surpassing its target. The company also secured an additional $10 million in funding under its existing debt agreement with Perceptive Advisors LLC and extended its minimum liquidity requirement to September 2026. Neuronetics aims to achieve positive cash flow from operations in 2025 and continues to focus on strategic priorities to drive sustainable growth.

The most recent analyst rating on (STIM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.

Spark’s Take on STIM Stock

According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.

Neuronetics’ overall stock score is influenced by ongoing financial challenges and negative valuation metrics. However, positive technical indicators and strategic initiatives, including successful acquisitions and leadership changes, provide some optimism for future performance.

To see Spark’s full report on STIM stock, click here.

More about Neuronetics

Neuronetics, Inc. is a vertically integrated, commercial stage medical technology and healthcare company that focuses on transforming the lives of patients with leading neurohealth therapies. The company primarily generates revenue from the sale and usage of its NeuroStar Advanced Therapy System, which is used in the treatment of depression.

Average Trading Volume: 873,214

Technical Sentiment Signal: Buy

Current Market Cap: $292.2M

For detailed information about STIM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1